The acquired resistance of mammary cancer cells to CDK4/6 inhibitors drives a DNA methylation reprogramming of genes encoding for BCL2 family members that confers a phenotype of high apopto-sensitivity induced by a BH3-mimetic drug

Autor: FRENEL, JEAN-SEBASTIEN, Voisin, Deborah, Nadaradjane, Arulraj, Bougras-Catron, Gwenola, Campone, Mario, Serandour, Aurelien, Cartron, Pierre-Francois

Publikováno v: San Antonio Breast Cancer Symposium
San Antonio Breast Cancer Symposium, Dec 2019, San Antonio, United States. pp.P4-04-09-P4-04-09, ⟨10.1158/1538-7445.SABCS19-P4-04-09⟩

International audience; Introduction. Due to the aberrant deregulation of the CDK4/6-INK4-RB pathway in breast cancer, CDK4/6 inhibitors are now a cornerstone of first line treatment of metastatic breast cancer showing an increase of progression free

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b9076c0457404ada875845d2ffa1cc09
https://www.hal.inserm.fr/inserm-03500281

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.